Vitrectomy combined with intravitreal triamcinolone acetonide injection for diabetic macular edema

Vitrectomy combined with intravitreal triamcinolone acetonide injection for diabetic macular edema - Vitrectomy combined with IVTA for DME

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017250

Enrollment

Registered

2015-05-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

Intra-Vitreal Triamcinolone Acetonide Vitrectormy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes Diabetic macular edema Foveal thickness more than 300 micrometers Intraocular pressure less than 21 mmHg Diagnosed as needed vitrectomy

Exclusion criteria

Exclusion criteria: History of previous vitrectomy. Previous history of treatment with agents including triamcninolone acetonide, anti-VEGF therapy, immunosuppressant drugs and artificial dialysis within 24 weeks. Modification of insulin treatments within 12 weeks. Previous history of laser treatments or intraocular surgery within 12 weeks. Previous history of systemic drugs such as steroid, carbonate dehydratase inhibitor and warfarin within 4 weeks.

Design outcomes

Primary

Measure	Time frame
Central retinal thickness	—

Countries

Japan

Contacts

Public ContactHiroshi Kunikata

Tohoku University Graduate School of Medicine Department of Ophthalmology

kunikata@oph.med.tohoku.ac.jp022-717-7294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026